Skip to content
Homepage
Author:
Calidi Biotherapeutics, Inc
Posted Date:
July 27, 2026
Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference
Calidi Biotherapeutics, Inc
July 27, 2026
Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers
Calidi Biotherapeutics, Inc
July 21, 2026
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
Calidi Biotherapeutics, Inc
July 20, 2026
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
Calidi Biotherapeutics, Inc
July 8, 2026
Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit
Calidi Biotherapeutics, Inc
June 24, 2026
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
Calidi Biotherapeutics, Inc
June 23, 2026
